Skip to content

Released Nov 3, 2015, after the close

10-Q filed Nov 3, 2015, 34 days after period end · 0001104659-15-075283

Q3 2015 · 10-Q
Revenue$1.03Mno prior Q3 2014 on file+211.9% vs Q2 2015
Net Income-$6.89MN/M vs Q3 2014N/M vs Q2 2015
EPS Diluted-$0.24N/M vs Q3 2014N/M vs Q2 2015
Operating Income-$6,328,000N/M
Operating Cash Flowderived-$7,131,000N/M
Free Cash Flowderived-$7,786,000N/M
Margins · derived
Operating margin-616.8%
Net margin-671.2%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2015Q3 2014Q3 2013Q3 2012
Revenue$1.03M—$209.00K$528.00K
Net Income-$6.89M-$6.60M-$6.07M-$4.11M
EPS Diluted-$0.24-$0.32-$4.81-$3.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR